We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 233

Court finds patent indefiniteness in unobtrusive claims

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • September 15 2014

In Interval Licensing LLC v. AOL, Inc., the Federal Circuit applied the test for patent indefiniteness set forth in the recent Supreme Court decision

Federal Circuit finds Apotex ANDAs do not infringe Lysteda patents

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • September 2 2014

In two decisions issued under the same name (Ferring B.V. V. Watson Laboratories, Inc.), the Federal Circuit upheld the validity of the Orange

Federal Circuit holds that even functional claims require structural fence posts

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • July 11 2014

In AbbVie Deutschland Gmbh v. Janssen Biotech, Inc., the Federal Circuit affirmed the district court decision that found AbbVie's patents directed to

Humira patent invalid for obviousness type double patenting

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • August 25 2014

In AbbVie Inc. v. Kennedy Institute of Rheumatology Trust, the Federal Circuit affirmed the district court's finding that a second patent covering

Federal Circuit upholds inequitable conduct defense against Apotex patent

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • August 18 2014

In Apotex Inc. v. UCB, Inc., the Federal Circuit upheld the district court's finding that Apotex's patent is unenforceable due to inequitable conduct

Federal Circuit invalidates Prandin patent claim as obvious

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • June 27 2013

In its third look at the Novo Nordisk AS patent related to Prandin, in Novo Nordisk AS v. Caraco Pharmaceutical Laboratories Ltd., the Federal

Federal Circuit clears way for generic Yasmin

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • April 26 2012

In Bayer Schering Pharma AG v. Lupin, Ltd., the Federal Circuit upheld the district court’s determination that the Abbreviated New Drug Applications at issue did not infringe the asserted patent related to Yasmin

Federal Circuit finds obviousness-type double patenting without common ownership

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • March 12 2013

Obviousness-type double patenting usually arises between commonly-owned patents or patent applications. While the USPTO has interpreted the

Federal Circuit upholds validity of Lysteda patents

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • August 28 2014

In two decisions issued under the same name (Ferring B.V. V. Watson Laboratories, Inc.), the Federal Circuit upheld the validity of the Orange

Federal Circuit holds the reexamination door open in In re Baxter

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • November 29 2012

When the Federal Circuit denied the Request for Panel Rehearing and Rehearing en banc in In re Baxter, the court let stand its two decisions that affirmed conflicting rulings on the validity of the same patent